IMV - IMV （IMV Inc.）

IMV Inc (NASDAQ: IMV ) announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (MVP-S), in combination with Merck & Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab) for relapsed, refractory Diffuse Large B Cell Lymphoma (r/r DLBCL). Related: Full story available on Benzinga.com

At closing bell on the New York Stock Exchange, the Dow Jones fell 2.25 percent to a one-month low, the S&P 500 index shed 2.49 percent and the NASDAQ Composite fell 3.23 percent. The leaders among Dow Jones index components in Thursday trading were shares of Verizon Communications Inc. which gained 0.32p (0.85%) to close at 37.77. Chevron Corp dropped 1.29p (0.75%) to close at 171.04. Walmart Inc shares shed 1.31p (0.89%) to close at 145.36. International Business Machines were the least gainers, with shares falling 7.50p (5.00%) to close the session at 142.36. Shares of Apple Inc soared 6.71p (4.69%) to 136.50, while Intel Corporation dropped 1.11p (3.93%) to 27.15. The gainers among S&P 500 index components in today''s trading were Lennar Corporation shares, which gained 3.82% to 94.29, DR Horton Inc. which gained 3.49% to close at 90.45 and Align Technology Inc. which gained 3.15% to close the session at 201.97. Western Digital Corporation shares were the least gainers, dropping 10.

IMV’s common shares expected to begin trading on a split-adjusted basis on December 13, 2022 DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass. — IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that […]

IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today provided an update on the open-label VITALIZE study evaluating its lead product maveropepimut-S (MVP-S) in combination with pembrolizumab and intermittent low-dose cyclophosphamide (CPA) in

IMV (IMV) said it was undertaking a reorganization and reducing its workforce by nearly one third.The company will focus on its DPX platform and advance its lead DPX asset…

IMV press release (IMV): Q2 GAAP EPS of -$0.12.Revenue of $0.03M (-25.0% Y/Y).On June 30, 2022, the Company had cash and cash equivalents of $31.1M and working capital of $27.7M,…

Companies Reporting Before The Bell • Magic Software (NASDAQ: MGIC ) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. • Dingdong (Cayman) (NYSE: DDL ) is likely to report earnings for its second quarter. • Evelo Biosciences (NASDAQ: EVLO ) is projected to report earnings for its second quarter. • Affimed (NASDAQ: AFMD ) is estimated to report quarterly loss at $0.17 per share on revenue of $8.67 million. • CorEnergy Infr Trust (NYSE: CORR ) is expected to report earnings for its second quarter. • Six Flags Entertainment (NYSE: SIX ) is expected to report earnings for its second quarter. • Where Food Comes From (NASDAQ: WFCF ) is projected to report earnings for its second quarter. • BurgerFi International (NASDAQ: BFI ) is estimated to report earnings for its second quarter. • Smith-Midland (NASDAQ: SMID ) is expected to report earnings for its second quarter. • Kala Pharmaceuticals (NASDAQ: KALA ) is expected to report earnings for its second quarter.

IMV (IMV) received a letter from Nasdaq for not meeting the minimum bid price of $1.00 per share required for continued listing.Company may be eligible for an additional 180 calendar…

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the first quarter ended March 31, 2022. “A top priority for 2022 is to accelerate MVP-S towards registration trials. The positive clinical data we presented on MVP-S in comb

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, May 13, 2022, at 8:00 a.m. ET to discuss the company’s 2022 first quarter financial and operational results. Financial analysts are invited to join the con